Silodosin as a medical expulsive therapy for distal ureteral stones: A systematic review and meta-analysis.

Autor:	Ramadhani MZ; Department of Urology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.; Dr. Soetomo General-Academic Hospital, Surabaya, East Java, Indonesia., Kloping YP; Department of Urology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.; Dr. Soetomo General-Academic Hospital, Surabaya, East Java, Indonesia., Rahman IA; Department of Urology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.; Dr. Soetomo General-Academic Hospital, Surabaya, East Java, Indonesia., Yogiswara N; Department of Urology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.; Dr. Soetomo General-Academic Hospital, Surabaya, East Java, Indonesia., Soebadi MA; Department of Urology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.; Universitas Airlangga/Rumah Sakit Universitas Airlangga Teaching Hospital, Surabaya, Indonesia., Renaldo J; Department of Urology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.; Dr. Soetomo General-Academic Hospital, Surabaya, East Java, Indonesia.
Jazyk:	angličtina
Zdroj:	Indian journal of urology : IJU : journal of the Urological Society of India [Indian J Urol] 2023 Jan-Mar; Vol. 39 (1), pp. 21-26. Date of Electronic Publication: 2022 Dec 29.
DOI:	10.4103/iju.iju_115_22
Abstrakt:	Introduction: Tamsulosin is the most commonly used medical expulsive therapy (MET). However, it does not alleviate ureteral colic. It is important to develop MET that can reduce ureteral colic while maintaining a high stone clearance rate. Silodosin is an α1A adrenoceptor with high affinity and selectivity for the distal ureter, which may reduce ureteral colic and enable stone expulsion for distal ureteral stones. Therefore, we performed this systematic review and meta-analysis to evaluate the efficacy of silodosin as MET and its role in reducing ureteral colic among patients with distal ureteral stones. Materials and Methods: This research was conducted in accordance with the Cochrane Handbook for Systematic Review and Intervention, in adherence with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses, and was registered in the International Prospective Register of Systematic Reviews (PROSPERO CRD42021249003). A comprehensive literature search was performed in several databases including Medline, EMBASE, and Scopus up to July 2021 for randomized trials comparing silodosin with placebo for MET. RevMan 5.4 was used for data analysis. Results: A total of six randomized controlled trials were included in this analysis with a total of 907 patients. Our analysis revealed that the patients who received silodosin had significantly higher stone expulsion rate (SER) (odds ratio [OR] 3.33, 95% confidence interval [CI] 2.34, 4.76, P < 0.01), significantly shorter stone expulsion time (SET) (mean difference -3.79, 95% CI -4.51, -3.06, P < 0.01), and lower analgesic use (OR 0.4, 95% CI 0.23, 0.69, P < 0.01) compared to the group receiving placebo. Conclusion: Silodosin showed significantly higher SER, lower SET and lower analgesic use in patients with distal ureteral stones as compared to a placebo. Competing Interests: Conflicts of Interest: There are no conflicts of interest. (Copyright: © 2022 Indian Journal of Urology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu